367 related articles for article (PubMed ID: 22897848)
21. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Ferreira AC; de-Freitas-Junior JC; Morgado-Díaz JA; Ridley AJ; Klumb CE
J Leukoc Biol; 2016 Apr; 99(4):569-78. PubMed ID: 26561567
[TBL] [Abstract][Full Text] [Related]
23. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
25. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
26. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
27. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis.
Penther D; Viailly PJ; Latour S; Etancelin P; Bohers E; Vellemans H; Camus V; Menard AL; Coutant S; Lanic H; Lemasle E; Drieux F; Veresezan L; Ruminy P; Raimbault A; Soulier J; Frebourg T; Tilly H; Jardin F
Genes Chromosomes Cancer; 2019 Aug; 58(8):595-601. PubMed ID: 30779244
[TBL] [Abstract][Full Text] [Related]
28. The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.
Truffinet V; Pinaud E; Cogné N; Petit B; Guglielmi L; Cogné M; Denizot Y
J Immunol; 2007 Nov; 179(9):6033-42. PubMed ID: 17947677
[TBL] [Abstract][Full Text] [Related]
29. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
30. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
31. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
32. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
33. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
[TBL] [Abstract][Full Text] [Related]
34. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
35. Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma.
Meznarich J; Miles R; Paxton CN; Afify Z
Pediatr Blood Cancer; 2016 May; 63(5):938-40. PubMed ID: 26785246
[TBL] [Abstract][Full Text] [Related]
36. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.
Molina-Privado I; Rodríguez-Martínez M; Rebollo P; Martín-Pérez D; Artiga MJ; Menárguez J; Flemington EK; Piris MA; Campanero MR
Cancer Res; 2009 May; 69(9):4052-8. PubMed ID: 19406837
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
38. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
Calado DP; Sasaki Y; Godinho SA; Pellerin A; Köchert K; Sleckman BP; de Alborán IM; Janz M; Rodig S; Rajewsky K
Nat Immunol; 2012 Nov; 13(11):1092-100. PubMed ID: 23001146
[TBL] [Abstract][Full Text] [Related]
39. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
40. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
